From Wikipedia, the free encyclopedia
Lamivudine/nevirapine/zidovudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Zidovudinenucleoside reverse transcriptase inhibitor
Clinical data
Trade namesDuovir-N, Zidovex-LN, others [1]
ATC code
Identifiers
CAS Number
ChemSpider
  • none

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [2] It contains lamivudine, nevirapine, and zidovudine. [2] It is either used by itself or along with other antiretrovirals. [2] It is a recommended treatment in those who are pregnant. [2] It is taken by mouth twice a day. [2]

The medication is generally well tolerated. [1] Side effects are those of the underlying medications. [2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain. [1] Use is not recommended in those with significant liver problems. [1] Use in pregnancy and breastfeeding appear to be safe. [1] The combination tablet is typically not appropriate for children. [2]

It is on the World Health Organization's List of Essential Medicines. [3] The combination is not commercially available in the United States as of 2018. [4]

See also

References

  1. ^ a b c d e "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  2. ^ a b c d e f g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl: 10665/44053. ISBN  9789241547659.
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.
From Wikipedia, the free encyclopedia
Lamivudine/nevirapine/zidovudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Zidovudinenucleoside reverse transcriptase inhibitor
Clinical data
Trade namesDuovir-N, Zidovex-LN, others [1]
ATC code
Identifiers
CAS Number
ChemSpider
  • none

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [2] It contains lamivudine, nevirapine, and zidovudine. [2] It is either used by itself or along with other antiretrovirals. [2] It is a recommended treatment in those who are pregnant. [2] It is taken by mouth twice a day. [2]

The medication is generally well tolerated. [1] Side effects are those of the underlying medications. [2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain. [1] Use is not recommended in those with significant liver problems. [1] Use in pregnancy and breastfeeding appear to be safe. [1] The combination tablet is typically not appropriate for children. [2]

It is on the World Health Organization's List of Essential Medicines. [3] The combination is not commercially available in the United States as of 2018. [4]

See also

References

  1. ^ a b c d e "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  2. ^ a b c d e f g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl: 10665/44053. ISBN  9789241547659.
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook